BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, Forrest JI, Harari O, Quirino Dos Santos CV, Guimarães de Almeida APF, Figueiredo Neto AD, Savassi LCM, Milagres AC, Teixeira MM, Simplicio MIC, Ribeiro LB, Oliveira R, Mills EJ; TOGETHER Investigators. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. JAMA Netw Open 2021;4:e216468. [PMID: 33885775 DOI: 10.1001/jamanetworkopen.2021.6468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
2 Sperna Weiland CJ, Smeets XJNM, Kievit W, Verdonk RC, Poen AC, Bhalla A, Venneman NG, Witteman BJM, da Costa DW, van Eijck BC, Schwartz MP, Römkens TEH, Vrolijk JM, Hadithi M, Voorburg AMCJ, Baak LC, Thijs WJ, van Wanrooij RL, Tan ACITL, Seerden TCJ, Keulemans YCA, de Wijkerslooth TR, van de Vrie W, van der Schaar P, van Dijk SM, Hallensleben NDL, Sperna Weiland RL, Timmerhuis HC, Umans DS, van Hooft JE, van Goor H, van Santvoort HC, Besselink MG, Bruno MJ, Fockens P, Drenth JPH, van Geenen EJM; Dutch Pancreatitis Study Group. Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021;6:350-8. [PMID: 33740415 DOI: 10.1016/S2468-1253(21)00057-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, Zohar S, Jaki T. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Stat Biopharm Res 2020;12:483-97. [PMID: 34191981 DOI: 10.1080/19466315.2020.1790415] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
4 Vanderbeek AM, Bliss JM, Yin Z, Yap C. Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemp Clin Trials 2021;112:106625. [PMID: 34793985 DOI: 10.1016/j.cct.2021.106625] [Reference Citation Analysis]
5 Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 2021;8:e175-84. [PMID: 33476571 DOI: 10.1016/S2352-3026(20)30373-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
6 Björklund MK, Cruickshank M, Lendrum RA, Gillies K. Randomised controlled trials in pre-hospital trauma: a systematic mapping review. Scand J Trauma Resusc Emerg Med 2021;29:65. [PMID: 34001219 DOI: 10.1186/s13049-021-00880-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pohl M, Baumann L, Behnisch R, Kirchner M, Krisam J, Sander A. Estimands-a Basic Element for Clinical Trials. Part 29 of a Series on Evaluation of Scientific Publications. Dtsch Arztebl Int 2021:arztebl. [PMID: 34857075 DOI: 10.3238/arztebl.m2021.0373] [Reference Citation Analysis]
8 Jacklin C, Rodrigues JN, Collins J, Cook J, Harrison CJ. Sample size calculations in high-profile surgical trials that use patient-reported outcome measures: systematic review. Br J Surg 2021:znab421. [PMID: 34915565 DOI: 10.1093/bjs/znab421] [Reference Citation Analysis]
9 Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen JC. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS Med 2020;17:e1003293. [PMID: 32941437 DOI: 10.1371/journal.pmed.1003293] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
10 Afolabi MO, Kelly LE. Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials. J Med Ethics 2021:medethics-2021-107263. [PMID: 34362828 DOI: 10.1136/medethics-2021-107263] [Reference Citation Analysis]
11 Granholm A, Alhazzani W, Derde LPG, Angus DC, Zampieri FG, Hammond NE, Sweeney RM, Myatra SN, Azoulay E, Rowan K, Young PJ, Perner A, Møller MH. Randomised clinical trials in critical care: past, present and future. Intensive Care Med 2021. [PMID: 34853905 DOI: 10.1007/s00134-021-06587-9] [Reference Citation Analysis]
12 Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. Health Technol Assess 2021;25:1-132. [PMID: 34590577 DOI: 10.3310/hta25570] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Krendyukov A, Singhvi S, Zabransky M. Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers. Front Oncol 2021;11:636561. [PMID: 33763370 DOI: 10.3389/fonc.2021.636561] [Reference Citation Analysis]
14 Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med 2020;18:352. [PMID: 33208155 DOI: 10.1186/s12916-020-01808-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason JMS. Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatol 2021;5:21. [PMID: 34210348 DOI: 10.1186/s41927-021-00192-5] [Reference Citation Analysis]
16 Luchini C, Veronese N, Nottegar A, Shin JI, Gentile G, Granziol U, Soysal P, Alexinschi O, Smith L, Solmi M. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat 2021;20:185-95. [PMID: 32935459 DOI: 10.1002/pst.2068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Wilson N, Biggs K, Bowden S, Brown J, Dimairo M, Flight L, Hall J, Hockaday A, Jaki T, Lowe R, Murphy C, Pallmann P, Pilling MA, Snowdon C, Sydes MR, Villar SS, Weir CJ, Welburn J, Yap C, Maier R, Hancock H, Wason JMS. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Med 2021;19:251. [PMID: 34696781 DOI: 10.1186/s12916-021-02124-z] [Reference Citation Analysis]
18 Sverdlov O, Ryeznik Y, Wong WK. Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field. Contemp Clin Trials 2021;105:106397. [PMID: 33845209 DOI: 10.1016/j.cct.2021.106397] [Reference Citation Analysis]
19 Grayling MJ, Mander AP. Accounting for variation in the required sample size in the design of group-sequential trials. Contemp Clin Trials 2021;107:106459. [PMID: 34082076 DOI: 10.1016/j.cct.2021.106459] [Reference Citation Analysis]
20 Renz BW, Adrion C, Klinger C, Ilmer M, D'Haese JG, Buhr HJ, Mansmann U, Werner J; PyloResPres Study Group. Pylorus resection versus pylorus preservation in pancreatoduodenectomy (PyloResPres): study protocol and statistical analysis plan for a German multicentre, single-blind, surgical, registry-based randomised controlled trial. BMJ Open 2021;11:e056191. [PMID: 34845079 DOI: 10.1136/bmjopen-2021-056191] [Reference Citation Analysis]